Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(4.10)
# 1,664
Out of 4,639 analysts
80
Total ratings
44.1%
Success rate
15.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERA Vera Therapeutics | Maintained: Buy | $100 | $31.00 | +222.58% | 12 | Aug 10, 2026 | |
| NVAX Novavax | Maintained: Buy | $18 | $7.88 | +128.43% | 3 | Aug 6, 2026 | |
| ATAI AtaiBeckley | Downgraded: Hold | n/a | $7.25 | - | 1 | Jul 16, 2026 | |
| PMN ProMIS Neurosciences | Initiated Coverage: Buy | $40 | $14.72 | +170.04% | 1 | Jun 29, 2026 | |
| AXSM Axsome Therapeutics | Maintained: Buy | $220 → $272 | $220.96 | +23.10% | 5 | May 4, 2026 | |
| ALEC Alector | Upgraded: Buy | n/a | $1.81 | - | 3 | Apr 15, 2026 | |
| RZLT Rezolute | Maintained: Hold | n/a | $4.68 | - | 6 | Mar 25, 2026 | |
| ALKS Alkermes | Maintained: Buy | $43 | $49.40 | -12.96% | 1 | Mar 11, 2026 | |
| CRVO CervoMed | Initiated Coverage: Buy | n/a | $3.12 | - | 1 | Dec 18, 2025 | |
| HELP Cybin | Reiterated: Buy | n/a | $9.96 | - | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $111.05 | - | 2 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.66 | n/a | 5 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.839 | n/a | 6 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $80.79 | n/a | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $7.13 | n/a | 7 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.35 | n/a | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $1.06 | n/a | 8 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $3.11 | n/a | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 | $6.71 | n/a | 4 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $2.43 | n/a | 3 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $25.75 | n/a | 3 | Jun 23, 2023 |
Vera Therapeutics
Aug 10, 2026
Maintained: Buy
Price Target: $100
Current: $31.00
Upside: +222.58%
Novavax
Aug 6, 2026
Maintained: Buy
Price Target: $18
Current: $7.88
Upside: +128.43%
AtaiBeckley
Jul 16, 2026
Downgraded: Hold
Price Target: n/a
Current: $7.25
Upside: -
ProMIS Neurosciences
Jun 29, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $14.72
Upside: +170.04%
Axsome Therapeutics
May 4, 2026
Maintained: Buy
Price Target: $220 → $272
Current: $220.96
Upside: +23.10%
Alector
Apr 15, 2026
Upgraded: Buy
Price Target: n/a
Current: $1.81
Upside: -
Rezolute
Mar 25, 2026
Maintained: Hold
Price Target: n/a
Current: $4.68
Upside: -
Alkermes
Mar 11, 2026
Maintained: Buy
Price Target: $43
Current: $49.40
Upside: -12.96%
CervoMed
Dec 18, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $3.12
Upside: -
Cybin
Oct 15, 2025
Reiterated: Buy
Price Target: n/a
Current: $9.96
Upside: -
Aug 22, 2025
Reiterated: Buy
Price Target: n/a
Current: $111.05
Upside: -
Jul 10, 2025
Reiterated: Buy
Price Target: n/a
Current: $3.66
Upside: n/a
Jul 7, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.839
Upside: n/a
Jul 2, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $80.79
Upside: n/a
Jul 1, 2025
Reiterated: Buy
Price Target: n/a
Current: $7.13
Upside: n/a
May 13, 2025
Reiterated: Buy
Price Target: n/a
Current: $5.35
Upside: n/a
Mar 3, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $1.06
Upside: n/a
Jan 10, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $3.11
Upside: n/a
Aug 8, 2023
Reiterated: Buy
Price Target: $34
Current: $6.71
Upside: n/a
Aug 8, 2023
Reiterated: Buy
Price Target: $13
Current: $2.43
Upside: n/a
Jun 23, 2023
Rated: Hold
Price Target: n/a
Current: $25.75
Upside: n/a